Principal Financial Group
ZVRA icon

Principal Financial Group’s Zevra Therapeutics ZVRA Stock Holding History

Principal Financial Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,610
Closed -$72K – 2545
2022
Q3 		$72K Sell
11,610
-20,394
-64% -$115K ﹤0.01% 2380
2022
Q2 		$143K Buy
+32,004
New +$146K ﹤0.01% 2345

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group's ZVRA Position: Q4 2022 in Review

Principal Financial Group sold out of Zevra Therapeutics (ZVRA) in Q4 2022, closing a stake of 11,610 shares — an estimated $72K sold.

Principal Financial Group first reported a position in ZVRA in Q2 2022 and held it in 2 quarters. The position peaked at $143K in Q2 2022. 69 funds tracked by Wall St. Rank hold ZVRA as of Q4 2022.

  • Principal Financial Group reported no remaining Zevra Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Principal Financial Group sold 11,610 Zevra Therapeutics shares in Q4 2022, an estimated $72K.
  • Principal Financial Group first reported a position in Zevra Therapeutics in Q2 2022 and held it in 2 quarters.
  • Principal Financial Group's Zevra Therapeutics position peaked at $143K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2022.

Based on Principal Financial Group's 13F filing for Q4 2022, filed 9 Feb 2023.